Generic placeholder image

Current Drug Targets

Editor-in-Chief

ISSN (Print): 1389-4501
ISSN (Online): 1873-5592

Targeting Aurora Kinases in Cancer Treatment

Author(s): Kevin R. Kelly, Jeffrey Ecsedy, Devalingam Mahalingam, Steffan T. Nawrocki, Swaminathan Padmanabhan, Francis J. Giles and Jennifer S. Carew

Volume 12, Issue 14, 2011

Page: [2067 - 2078] Pages: 12

DOI: 10.2174/138945011798829410

Price: $65

Abstract

The Aurora family of serine/threonine kinases is essential for chromosome alignment, segregation, centrosomal maturation, mitotic spindle formation, and cytokinesis during mitosis. Their fundamental role in cell cycle regulation and aberrant expression in a broad range of malignancies prompted the development of small molecules that selectively inhibit their activity. Recent studies have revealed new insights into the cellular effects of Aurora kinase inhibition. Moreover, early phase clinical studies have shown that these agents have therapeutic efficacy. In this review, we will outline the functions of Aurora kinases in normal cell division and in malignancy. We will focus on recent preclinical and clinical studies that have explored the mechanism of action and clinical effect of Aurora inhibitors in cancer treatment.

Keywords: Aurora kinase inhibitors, cancer, tageted therapy, mitosis, clinical studies, cell cycle regulation, malignancy, Hesperadin, ZM447439, AT9283


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy